Humulin-R

DRUG3 trials

Sponsors

Halozyme Therapeutics

Conditions

Diabetes MellitusDiabetes Mellitus, Type 2Type 1 Diabetes Mellitus

Phase 1

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

CompletedNCT00705536

Halozyme TherapeuticsDiabetes Mellitus

Start: 2007-12-31End: 2008-02-29Updated: 2019-02-26

Phase 2

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

CompletedNCT00774800

Halozyme TherapeuticsType 1 Diabetes Mellitus

Start: 2008-10-31End: 2009-03-31Updated: 2019-02-26

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

CompletedNCT00916357

Halozyme TherapeuticsDiabetes Mellitus, Type 2

Start: 2009-07-31End: 2009-11-30Updated: 2014-08-18